New immunosuppressants in BMT/GVHD.
Basara
N
N
Department of Hematology/Oncology, BMT Unit, Oberstein, Germany.
Günzelmann
S
S
Willenbacher
W
W
Fauser
A A
AA
Kiehl
M G
MG
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D016026:Bone Marrow Transplantation / Q000276:immunology*; D003587:Cytomegalovirus / Q000502:physiology; D003586:Cytomegalovirus Infections / Q000503:physiopathology; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D006086:Graft vs Host Disease / Q000188:drug therapy* / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use*; D014775:Virus Activation
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D000077561:Daclizumab; D009173:Mycophenolic Acid